Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rituximab Use Increasing in Treatment of Pediatric Vasculitis

Catherine Kolonko  |  Issue: December 2017  |  December 20, 2017

Rituximab is an antibody drug used to treat some cancers and autoimmune diseases.<br /> ellepigrafica / SHUTTERSTOCK.COM

(click for larger image)
Rituximab is an antibody drug used to treat some cancers and autoimmune diseases.

ellepigrafica / SHUTTERSTOCK.COM

According to a large cohort study of pediatric patients, rituximab use is on the rise in the treatment of children diagnosed with vasculitis. Treatment with cyclophosphamide remains common, but it’s beginning to wane. Dialysis and mechanical ventilation also remain common, the study indicates.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The retrospective study of hospitalized children in the U.S. included the largest cohort of pediatric-onset anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) patients to date, according to lead author Karen E. James, MD, a pediatric rheumatologist who conducted the study while at Children’s Hospital of Philadelphia. The researchers published the study’s results, spanning more than a decade of data, in the September issue of Arthritis Care & Research.1

AAV causes inflammation of blood vessels that can lead to organ failure (mostly in the lungs and kidneys) and life-threatening morbidity. Dr. James says medical treatment for children with AAV is often based on physician experience combined with data learned from adult-only clinical trials.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“There has been a lot of research in the past 20 years looking at ANCA-associated vasculitis and its different subtypes in adults, and there have been a lot of advances in the medicines that treat them,” says Dr. James, now an instructor in pediatric rheumatology at the University of Utah School of Medicine and Primary Children’s Medical Center in Salt Lake City. “But nobody’s really looked at it in kids, and like a lot of rheumatologic diseases, it’s rarer in kids.”

The Rise of Rituximab

Dr. James

Dr. James

Historically, doctors have treated adults with high doses of glucocorticoids in combination with cyclophosphamide to induce remission. Cyclophosphamide is an immunosuppressive agent doctors also use in some forms of chemotherapy, and it’s been associated with serious morbidities, such as infection, hemorrhagic cystitis, infertility and malignancy, according to the study.

The treatment landscape began to change after two landmark studies in 2010 found that rituximab was not inferior to cyclophosphamide for the induction of remission of severe AAV, says Dr. James. Later studies showed the drug also proved efficacious in maintaining remission.2,3

“Our study demonstrates a gradual decline in the use of cyclophosphamide, a gradual increase in the use of plasma exchange and an exponential increase in the use of rituximab, indicating the data from the adult studies have influenced treatment paradigms in children,” the study authors write.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsPediatric ConditionsResearch RheumVasculitis Tagged with:AAVAC&RAmerican College of Rheumatology (ACR)antibody-associated vasculitisArthritis Care & ResearchChildrenClinicalcyclophosphamideDiagnosisdrugoutcomepatient carePediatricResearchrheumatologistrheumatologyrituximabstudytherapytreamentVasculitis

Related Articles

    ANCA-Associated Vasculitis Trial Results May Change Standard of Care

    May 15, 2020

    SNOWMASS VILLAGE, COLO.—The study of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is ongoing, and research results should help improve treatment for this patient pop­ulation. Key trials and therapeutic options were discussed at the 2020 ACR Winter Symposium during the session, Update on the Treatment of ANCA-Associated Vasculitis, by Peter A. Merkel, MD, MPH, chief of…

    Vasculitis Guidelines in Focus, Part 2: ANCA-Associated Vasculitis

    September 9, 2021

    Sharon Chung, MD, MAS, discusses specific recommendations for the treatment and management of ANCA-associated vasculitis from the latest ACR Guideline.

    Maintenance of Remission in ANCA-Associated Vasculitis

    September 5, 2012

    Relapses are common, but difficult to predict and prevent.

    How to Manage Pain in Patients with Renal Insufficiency or End-Stage Renal Disease on Dialysis

    October 1, 2013

    Narcotic and non-narcotic pain regimens can be used

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences